948 results about "Endocrine secretion" patented technology

In various embodiments, the disclosure provides compositions, such as polypeptides, polynucleotides, gene editing systems, small molecules, vectors, or host cells, comprising and / or modulating the expression or activity of an immunomodulatory-related protein. In various embodiments, the disclosure also provides for the treatment of aging, senescence, fibrosis, metabolic diseases, cardiovascular diseases, endocrine-related disorders, genetic diseases, cancer, infections, immune diseases, and the like using agents comprising and / or modulating the expression or activity of an immunomodulatory-related protein. Methods of replacing an adaptation of therapy or combinations thereof with hormones, growth factors and / or proteins, as well as methods of identifying the agents.

The present invention relates to various molecular constructs having at least one cellular-targeting element, one protein-targeting element, and one ubiquitin ligase recruitment element, wherein these elements are conjugated in a manner that facilitates cellular uptake and targeted degradation of specific proteins within cells. The present invention further relates to multifunctional proteolysis-targeting chimera conjugates and uses thereof for the treatment of diseases or disorders such as immune and inflammatory diseases, infectious diseases, cardiovascular diseases, endocrine disorders, and various cancers that are otherwise resistant to traditional therapeutic regimens.

The invention discloses a health degree assessment system and method for endocrine nursing, and relates to the technical field of health assessment, and the system comprises a state vector construction module which is used for collecting basic data of a patient, constructing an individual state vector S, collecting physiological data of the patient in real time, and extracting deep features by using a CNN model; and the anomaly detection module is used for performing dimensionality reduction on the deep features by using PCA, then inputting a mutation point detection algorithm to detect periodic mutation points to obtain a mutation point set, identifying peak activation response by using SNN to obtain a peak anomaly set, and integrating the obtained mutation point set and the peak anomaly set into an anomaly feature vector A. According to the method, dynamic and accurate evaluation of the health state of the endocrine patient is achieved, accurate multi-symptom risk prediction can be achieved through real-time monitoring and automatic recognition of hormone fluctuation, behavior abnormity and health state changes, a personalized nursing intervention plan can be generated according to the individual health state, and therefore the nursing efficiency is improved.

The invention relates to the technical field of intelligent medical treatment, in particular to an endocrine patient health management method and system integrated with an electronic medical record. The method comprises the following steps: performing multi-dimensional data acquisition of an endocrine patient through a hospital information system, and performing multi-dimensional portrait construction of the patient to obtain a multi-dimensional health portrait of the patient; performing time sequence data feature extraction on the multi-dimensional health portrait of the patient to obtain time sequence feature data; acquiring historical physiological data of the patient; establishing an individualized physiological rhythm model according to the historical physiological data of the patient to obtain the individualized physiological rhythm model; and performing non-uniform interpolation on the time sequence characteristic data according to the individualized physiological rhythm model to obtain interpolated data. According to the method, the individualized physiological rhythm model and the dynamic baseline model are constructed, the dynamic early warning threshold value and subtype layering are combined, and accurate risk assessment and individualized health information management are performed on each patient, so that the health management effect is remarkably improved.

The invention relates to the technical field of database construction, in particular to a construction method and system for a reproductive medicine database. The method comprises the following steps: acquiring a biological tissue sample of a patient; acquiring reproductive endocrine hormone data, embryo morphological parameter data, immune cell function data and genome variation data from the biological tissue sample of the patient; performing time sequence analysis processing on the hormone fluctuation mode according to the reproductive endocrine hormone data to obtain endocrine dynamic characteristic data; performing image recognition processing based on coherent superposition characteristics of light on the embryo morphological parameter data, and performing embryo development potential evaluation to obtain embryo development potential data; and performing hierarchical clustering processing on the individual heterogeneity of the patient according to the immune cell function data and the genome variation data to obtain immune-genetic typing data of the patient. By means of the quantum dot sensing technology and the multi-channel micro-fluidic chip, standardization of data acquisition is achieved, and the heterogeneity problem of a data source is solved.

The invention discloses an endocrine disrupter prediction method based on a harmful outcome path network, and belongs to the field of endocrine, and the method comprises the steps: obtaining experimental activity data containing qualitative data and quantitative data according to a pre-constructed harmful outcome path network; acquiring endocrine disrupter list data as a second data set; constructing a target spot qualitative prediction model according to the qualitative data; performing target activity data prediction on the second data set by using a target qualitative prediction model to obtain a target activity data set; constructing an endocrine disruption effect qualitative prediction model by using the target activity data set; constructing a target spot quantitative prediction model according to the quantitative data; predicting whether the compound to be detected has the endocrine disruption effect or not by utilizing the endocrine disruption effect qualitative prediction model; and for the compound with the endocrine interference effect, predicting the corresponding target quantitative activity by using the target quantitative prediction model to obtain a quantitative harmful outcome path. According to the method, the endocrine disrupter EDCs is qualitatively identified and quantitatively classified.

The invention belongs to the field of biological medicines, and particularly relates to application of FeTMPyP in preparation of a medicine for relieving ovarian toxicity. FeTMPyP is selected as an intervention agent aiming at the fact that MC-LR and NaNON combined exposure can remarkably induce mouse ovary nitration stress, mouse follicle barrier damage and ovarian reproductive endocrine dysfunction; the FeTMPyP can be used for effectively relieving nitration stress induced by combined exposure of MC-LR and NaNO2 in mouse ovaries, improving sex hormone disorder, disordered estrus cycle and follicular atresia phenomena caused by combined exposure of the two poisons, and recovering the fertility of the mouse, so that the intervention of the FeTMPyP can be used for relieving the mouse ovarian toxicity induced by combined exposure of MC-LR and NaNO2, and can be used for treating the ovarian toxicity of the mouse caused by combined exposure of the MC-LR and NaNO2. The compound can be used for preparing medicines for preventing and treating related diseases such as mouse ovarian toxicity caused by environmental toxin exposure, and a new way is provided for early recognition and targeted intervention of ovarian related diseases.

This application discloses a rapid detection method for screening of dwarfism in children, which belongs to the field of intelligent medical technology. It includes the following steps: Step 1, accurately sampling through capillary effect, and automatically diluting the sample to ensure accurate concentration; Step 2, introducing the collected sample into a multi-channel microfluidic detection chip to achieve parallel quantitative detection of endocrine hormones; Step 3, real-time acquisition and amplification of weak biomolecule recognition signals to effectively improve the signal-to-noise ratio; Step 4, multi-dimensional analysis of the test results to achieve quantitative evaluation of growth and development, body mass index and sexual development indicators and risk prediction of endocrine diseases; Step 5, automatically integrating the analysis results and generating a standardized test report; Step 6, establishing a quality control mechanism throughout the entire detection process, including real-time monitoring of sample quality, tracking of detection process parameters, result consistency evaluation, and full traceability of detection data.

The invention discloses a prostate cancer endocrine therapy drug resistance prediction system based on multi-model artificial intelligence. The prostate cancer endocrine therapy drug resistance prediction system comprises a data acquisition and preprocessing module, a single omics prediction module, a multi-modal feature integration module, a model training module and a prediction result output module. Multi-omics data of a patient is collected and preprocessed, data representations of omics data of different labels are generated by using priori knowledge, and an optimal single-omics prediction model is matched for the omics data of different labels based on the data representations after knowledge enhancement. And constructing a multi-omics prediction model of the prostatic cancer endocrine treatment drug resistance by using the optimal single-omics prediction model corresponding to the different label medical data by adopting Stacking, predicting the drug resistance risk of the patient within a preset time, outputting an early warning, and adjusting the treatment scheme of the patient according to the drug resistance risk. According to the method, the multi-omics data are integrated, the accurate multi-omics prediction model for the drug resistance of the endocrine therapy of the prostate cancer is constructed, and the accuracy and clinical applicability of drug resistance prediction are improved.

Disclosed herein are compositions and methods related to differentiation of stem cells into pancreatic endocrine cells. In some aspects, the methods provided herein relate to generation of pancreatic β cell, α cell, δ cells, and EC cells in vitro. In some aspects, the disclosure provides pharmaceutical compositions including the cells generated according to the methods disclosed herein, as well as methods of treatment making use thereof.

The invention discloses an application of isorhamnetin-3-O-neohesperidin in preparation of a medicine for preventing and / or treating benign prostatic hyperplasia. In-vitro experiments show that the isorhamnetin-3-O-neohesperidin can inhibit proliferation of prostatic hyperplasia cells, promote apoptosis of the prostatic hyperplasia cells and regulate inflammatory response of the prostatic hyperplasia cells, and rat experiments show that the isorhamnetin-3-O-neohesperidin can improve the hormone endocrine disorder condition of an animal model body, and can inhibit the prostatic hyperplasia cells and promote the prostatic hyperplasia cell apoptosis and regulate the inflammatory response of the prostatic hyperplasia cells. The anti-inflammatory ability of an animal model is enhanced, and the traditional Chinese medicine composition has a relatively good treatment effect on prostatic hyperplasia caused by testosterone propionate. The medicine for preventing and / or treating benign prostatic hyperplasia, provided by the invention, contains a pharmacodynamic dose of isorhamnetin-3-O-neohesperidin and a pharmaceutically acceptable carrier or auxiliary material, can be prepared into a medicine dosage form which is convenient for clinical use and can play an optimal curative effect, and has a relatively high clinical application value.

The invention discloses an endocrine health monitoring method and system based on artificial intelligence. The method comprises the following steps: S1, generating a preprocessed standard physiological signal data set; s2, constructing an initial physiological state map based on the preprocessed standard physiological signal data set to form an initial physiological state map; s3, expanding and refining the preliminary physiological state atlas, constructing a multilayer heterogeneous physiological state atlas, and forming a combined physiological state atlas comprehensively reflecting various physiological interaction mechanisms; s4, outputting graph embedding representation reflecting the states of the endocrine glands and the dynamic linkage relation of the endocrine glands; and S5, on the basis of the graph embedding representation, analyzing and judging the linkage state of each gland in the endocrine system by using a preset anomaly judgment strategy, detecting a node or edge relationship with an abnormal mode, and outputting an anomaly monitoring result serving as anomaly early warning information. The endocrine health monitoring precision can be improved.

The invention discloses a 3D intestinal organ differentiation method based on human pluripotent stem cells and an induction culture medium and application thereof, and relates to the technical field of stem cells. According to a culture medium formula combination, intestinal organs can be differentiated into various cell types such as epithelial cells, neuroendocrine cells and endothelial cells; the method is a key mark for successful differentiation and functional maturation of intestinal organs. According to the 3D intestinal organ differentiation method disclosed by the invention, histological structures such as intestinal crypts are differentiated from intestinal organs generated by differentiation, and the intestinal organs can creep in a maintenance stage, so that the intestinal organs are changed from structural bionics to functional simulation, and the significance of the 3D intestinal organ differentiation method is far better than that of pure morphological simulation. Through a systematic culture medium formula, a clear operation process and a multi-stage induction strategy, the 3D intestinal organ with structural integrity, cell diversity and functional activity is successfully constructed, and the system provides an efficient, reliable and extensible in-vitro model platform for intestinal biological research and related application.

The invention relates to the technical field of medical health management, and discloses an endocrine patient health management system based on big data. According to the system, a multi-source data acquisition module is adopted to acquire heterogeneous health data including physiological monitoring indexes, medication record data, medical image reports and the like, and living habit logs can also be included. The physiological feature noise reduction module is used for extracting steady-state physiological features, the multi-modal fusion module is used for generating a focus dynamic map, and the medication feedback analysis module is used for generating a drug response mode evolution sequence. The data are input into a multi-dimensional decision model, and a health management scheme is output by a personalized scheme generation module. And the living habit analysis module analyzes the living habit logs to generate influence factors, and participates in making a health management scheme. The system realizes multi-source data fusion analysis, can provide a personalized health management scheme for an endocrine patient, improves the disease diagnosis accuracy and treatment effect, and improves the life quality of the patient.

The invention discloses an endocrine disruption effect harmful outcome path network construction method, and relates to the field of endocrine disrupter screening, and the method comprises the steps: obtaining endocrine data; preprocessing the acquired endocrine data; according to the preprocessed endocrine data, constructing an event causal relationship triad reflecting the endocrine disruption effect, wherein the event causal relationship triad comprises a trigger word, a source event and a target event; the data KER1 is used as data KER1; according to the preprocessed endocrine data, acquiring endocrine data of which the confidence coefficient is greater than a preset threshold value from a preset literature database, and taking the acquired endocrine data as data KER2; performing duplicate removal processing on the data KER1 and the data KER2 to obtain final endocrine disruption effect harmful outcome path data; and establishing an endocrine disruption effect harmful outcome path network according to the final endocrine disruption effect harmful outcome path data. In view of insufficient analysis of an action mechanism between an endocrine disrupter and a corresponding bad health outcome in the prior art, the application improves interpretability.

The invention discloses a method for establishing a co-culture system of porcine skeletal muscle satellite cells (PSCs) and porcine kidney fibroblasts (PKFs). The method comprises the following steps of: performing in-vitro induction on the PKFs to transdifferentiate into adipocytes, optimizing a process of the method, establishing an optimal PSCs and PKFs co-culture induced differentiation method, and selecting a co-culture proportion. According to the method for in-vitro induction of PKFs transdifferentiation and the co-culture system of PKFs and PSCs established by the invention, the PKFs can replace porcine precursor adipocytes (ADSCs) to serve as a source of seed cells in artificial meat fat, and the period of adipogenesis induced differentiation is shortened; the established PKFs and PSCs co-culture system provides a new two-dimensional model for the artificial snowflake meat; a powerful in-vitro model is provided for deep understanding of intercellular interaction and endocrine and paracrine functions of the skeletal muscle which is a highly heterogeneous tissue.

The invention discloses a classification method and a classification device for pancreatic neuroendocrine tumors. The classification method comprises the following steps: using a pre-trained segmentation model to segment a plurality of HE full slice images from a plurality of patients; quantizing each segmented HE full slice image to determine a plurality of first feature parameters; based on the cellular morphology and topological features of each HE full-slice image, extracting a plurality of second feature parameters from each HE full-slice image; for each HE full slice image, screening out a target feature from the plurality of first feature parameters and the plurality of second feature parameters, and calculating a pathological omics score; inputting the pathological omics scores and the conventional pathological features of the plurality of HE full slice images into a logistic regression model for training to obtain a trained logistic regression model; and classifying the HE full slice images to be classified by using the logistic regression model. According to the method, pancreatic neuroendocrine tumor G classification can be quickly and accurately realized at low cost.

The invention provides a hypoglycemic peptide which is prepared by taking bovine whey protein as a raw material and is stable in gastrointestinal digestion and absorption. In an in-vitro cell experiment, the peptide fragment can improve the uptake of insulin-resistant HepG2 hepatocytes and synthesize glycogen by using glucose, can promote intestinal endocrine cells NCI-H716 to secrete GLP-1, has a certain synergistic effect, and can further play the effects of promoting GLP-1 secretion and activating a GLP-1 receptor through combined use. An insulin resistance mouse model is constructed by utilizing high-fat diet, and the peptide fragment is adopted for intervention, so that the hypoglycemic peptide is further proved to have obvious effects on losing weight, reducing lipid accumulation and assisting in reducing blood fat, and meanwhile, the hypoglycemic peptide can be used for improving insulin resistance related symptoms. The milk peptide provided by the invention has gastrointestinal digestion stability and hypoglycemic activity, can be used as a functional milk base material for developing food, medicines or health care products with the effect of regulating blood sugar, and is wide in application prospect.

Described herein are compounds useful in the treatment of TYK2 mediated diseases. In some embodiments, the TYK2-mediated disease is an autoimmune disease, an inflammatory disease, a proliferative disease, an endocrine disease, a neurological disease, or a disease associated with transplantation.

The invention relates to the technical field of blood pressure dynamic monitoring systems, and provides an artificial intelligence-based blood pressure dynamic monitoring and risk assessment system, which comprises a patient terminal, a doctor terminal, a data center terminal, a local anomaly detection terminal and a strategy generation terminal, the patient terminal is used for collecting blood pressure, body position change and endocrine hormone fluctuation data of a patient in real time; the data center terminal is used for fusing, storing and processing the data uploaded by the patient terminal and performing overall risk assessment; the local anomaly detection terminal is used for collecting local blood flow rate and pulse wave conduction velocity data and carrying out local anomaly detection index analysis; the strategy generation terminal is used for generating strategy information according to the overall risk assessment result and the local anomaly detection index; and the doctor terminal is used for receiving and displaying the overall risk assessment result and the local anomaly detection index, and receiving and executing the strategy information. According to the invention, the comprehensiveness and timeliness of hypertension risk prediction and intervention are improved.

The invention relates to the technical field of medical syringes, and discloses an endocrine hormone injection auxiliary device, which comprises a syringe mechanism, a needle cylinder mechanism, a needle cylinder mechanism, a needle cylinder mechanism and a needle cylinder mechanism, and the constant pressure mechanism is arranged on the needle cylinder and is used for providing constant pressure to drive the cylinder piston. According to the endocrine hormone injection auxiliary device, a constant-pressure mechanism is arranged, based on the conversion principle of gravity and air pressure, the gravity is converted into constant air pressure by placing a weight with the fixed weight on a top light disc, and a cylinder piston is pushed to move in a needle cylinder at the uniform speed; and the problem of unstable injection speed caused by non-uniform hand force during manual injection is avoided. Meanwhile, the moving distance of the top light disc is accurately controlled by rotating the threaded rod, then the amount of air extruded out of the middle corrugated pipe is determined, accurate control over the liquid medicine output amount is achieved, and the requirements of patients with chronic diseases or the weak for accurate, stable and slow injection are met.

The invention relates to the field of medical application, in particular to application of nerve-soothing and brain-strengthening liquid to preparation of medicine for treating or preventing chronic fatigue syndrome. According to the invention, the nerve-soothing and brain-strengthening liquid is used for research on treatment or prevention of chronic fatigue syndrome for the first time. By establishing an intraperitoneal injection polyinosinic-cytidylic acid composite swimming induced CFS mouse model and a multi-factor composite stress induced CFS rat model, and by means of an exhaustive swimming experiment, a tail suspension experiment, a mechanical pain threshold, a Bannes maze and a pentobarbital sodium sleep experiment, an endocrine function, an immunologic function, skeletal muscle energy metabolism and other modes are detected, and the skeletal muscle energy metabolism can be detected. It is found that the nerve soothing and brain strengthening liquid can improve the CFS symptoms shown by mice and rats of the two models.

The invention discloses an application of enzymatic casein in promotion of porcine endocrine cell proliferation, belongs to the technical field of animal nutrition and feed, and provides an application of enzymatic casein in promotion of porcine endocrine cell proliferation, which does not aim at diagnosis and treatment of diseases. The invention provides a method for promoting pig endocrine cell proliferation by using casein enzymolysis. The method comprises the following steps: adaptively feeding pigs with daily ration with the crude protein content of 13% for 7 days; mixing the daily ration with the crude protein content of 13% with the enzymolysis casein according to the mass ratio of 95.5: 4.5 to obtain the daily ration containing the enzymolysis casein, and feeding twice a day for 28 days. According to the invention, a certain proportion of casein hydrolysate is added into the feed to regulate and control microbe composition of small intestinal mucosa of growing pigs, so that proliferation of small intestinal endocrine cells is further regulated, the secretion level of gastrointestinal hormone is increased, the gastrointestinal transport function of animals is finally enhanced, the absorption of nutrient substances is accelerated, and the growth performance of the pigs is improved.

Exemplary embodiments described herein relate to a closed loop artificial pancreas system. The artificial pancreas system seeks to automatically and continuously control the blood glucose level of a user by emulating the endocrine functionality of a healthy pancreas. The artificial pancreas system uses a closed loop control system with a cost function. The penalty function helps to bound the infusion rate of insulin to attempt to avoid hypoglycemia and hyperglycemia. However, unlike conventional systems that use a generic or baseline parameter for a user's insulin needs in a cost function, the exemplary embodiments may use a customized parameter in the cost function that reflects the individualized insulin needs of the user. The use of the customized parameter causes the cost function to result in insulin dosages over time better suited to the individualized insulin needs of the user. This helps to better avoid hypoglycemia and hyperglycemia.

The invention discloses an endocrine disrupter quantitative activity prediction method, and relates to the field of endocrine disrupter virtual screening, and the method comprises the following steps: obtaining nuclear receptor in vitro experiment data, removing repeated data in the experiment data, and removing a compound set which does not contain simplified molecular linear input specification SMILES expression; a molecular fingerprint method is adopted to extract first-level, second-level and third-level feature structures of the compound. For each compound cluster, constructing a quantitative prediction model based on machine learning or quantitative read-stress for predicting the quantitative activity value of the compound; aiming at the low quantitative activity prediction efficiency of the endocrine disrupter in the prior art, multilevel structure characteristics of compounds are extracted, and corresponding quantitative prediction models are constructed for compound structure clusters of different scales. Through molecular docking and molecular dynamics simulation, the interaction mechanism and the like of the endocrine disrupter and the nuclear receptor are researched from the perspective of structural biology, and the efficiency is improved.

The invention discloses DLL3 serving as a cervical neuroendocrine cancer treatment target and application of the DLL3, and belongs to the technical field of biology. The invention discloses specific expression of a DLL3 gene in cervical neuroendocrine carcinoma (NECC) and application of the DLL3 gene as a therapeutic target. Single cell sequencing and immunohistochemistry find that a DLL3-NOTCH1 / 2 signal axis is activated in NECC, and functional experiments prove that the DLL3-NOTCH1 / 2 signal axis drives malignant progression by promoting tumor proliferation and inducing T cell depletion. In addition, the invention also constructs an NECC organ-TILs co-culture model, and verifies the synergistic effect of the DLL3 targeted drug AMG757 combined with EP chemotherapy. The invention provides new target selection and theoretical basis for precise diagnosis and treatment of NECC, and has important clinical transformation value.

The utility model provides a thermal steaming type belly health care waistband which comprises a waistband body tied to the waist and belly of a human body, a breathable storage bag used for containing a traditional Chinese medicine bag is arranged on the inner side wall, right facing the belly of the human body, of the waistband body, and a water vapor generating device is arranged on the outer side wall, right facing the belly of the human body, of the waistband body. The water vapor generating device is right opposite to the storage bag, air holes communicated with the storage bag are formed in the outer side wall, right opposite to the abdomen of the human body, of the waistband body, and hot steam generated by the water vapor generating device enters the storage bag through the air holes to conduct hot steaming on a traditional Chinese medicine bag placed in the storage bag. The medicinal materials in the traditional Chinese medicine bag are promoted to release medicinal gas by utilizing a hot steaming principle, so that the medicinal gas is fully released and acts on the abdomen of a human body, and the effects of the traditional Chinese medicines are improved, thereby improving the hormone level in the body and regulating the metabolic function and endocrine function.

The invention provides a preparation method of 1-(3-bromo-4-(2-fluoro [18F] ethyoxyl) ethyoxyl) benzyl guanidine (called 18F-TTRC01) and application of the 1-(3-bromo-4-(2-fluoro [18F] ethyoxyl) ethyoxyl) benzyl guanidine in the field of neuroendocrine tumor diagnosis. The compound is synthesized through the following route. According to the invention, a brand new initial raw material and a preparation route are adopted, a large dose of 18F ions are used for labeling, and an automatic synthesis mode is adopted to successfully prepare the 18F-TTRC01, so that the reaction time is greatly shortened, and the radiation dose to operators is reduced. The obtained 18F-TTRC01 injection can be used for diagnosis and curative effect evaluation of neuroendocrine tumors, and has an outstanding clinical effect. # imgabs0 #

The invention relates to the field of animal consumer goods, and particularly discloses application of glucan in preparation of animal products for relieving pet stress syndromes. Pet experiments find that beta-1, 3 / alpha-1, 3-glucan can improve the stress syndromes of the indoor cats, specifically, abnormal behaviors of the cats are corrected, and abnormity of multiple systems of organisms such as the immune system, the endocrine system and the urinary system is improved. And when the method is applied to pets, the life quality of the pets can be remarkably improved, more emotional support is provided for pet owners, and the method has practical popularization and application values.

Novel compounds that act as antagonists to human GPR39 protein are disclosed. Pharmaceutical compositions and methods of use for antagonists to human GPR39 protein are disclosed. In particular, methods of using the antagonists in the treatment of diseases or conditions including cardiovascular conditions, endocrine system and hormone disorders, cancer disorders, metabolic diseases, gastrointestinal and liver diseases, hematological disorders, neurological disorders and respiratory diseases are disclosed herein.